The Procter & Gamble Company (PG) Stock Forecast
Data as of May 2, 2026Consumer Defensive · Current price $147.34 (+0.19%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 23, 2026 | Chris Carey | Wells Fargo | $165.00 | +12.0% |
| Jan 16, 2026 | Lauren Lieberman | Barclays | $155.00 | +5.2% |
| Jan 14, 2026 | Peter Grom | UBS | $161.00 | +9.3% |
| Oct 8, 2025 | Peter Grom | UBS | $176.00 | +19.5% |
| Oct 1, 2025 | Lauren Lieberman | Barclays | $153.00 | +3.8% |
| Jul 30, 2025 | Peter Grom | UBS | $180.00 | +22.2% |
| May 1, 2025 | Edward Lewis | Redburn Partners | $161.00 | +9.3% |
| Apr 25, 2025 | Dara Mohsenian | Morgan Stanley | $180.00 | +22.2% |
| Jan 23, 2025 | Lauren Lieberman | Barclays | $159.00 | +7.9% |
| Dec 5, 2024 | Kaumil Gajrawala | Jefferies | $174.00 | +18.1% |
| Nov 22, 2024 | Mark Astrachan | Stifel Nicolaus | $167.00 | +13.3% |
| Oct 21, 2024 | Bill Chappell | Truist Financial | $180.00 | +22.2% |
| Oct 21, 2024 | Nik Modi | RBC Capital | $164.00 | +11.3% |
| Oct 21, 2024 | Linda Bolton Weiser | D.A. Davidson | $160.00 | +8.6% |
| Oct 21, 2024 | Olivia Tong | Raymond James | $190.00 | +29.0% |
| Oct 9, 2024 | Linda Bolton Weiser | D.A. Davidson | $159.00 | +7.9% |
| Oct 4, 2024 | Bonnie Herzog | Goldman Sachs | $164.00 | +11.3% |
| Sep 30, 2024 | Lauren Lieberman | Barclays | $163.00 | +10.6% |
| Sep 23, 2024 | Korinne Wolfmeyer | Piper Sandler | $174.00 | +18.1% |
| Sep 16, 2024 | Kevin Grundy | BNP Paribas | $192.00 | +30.3% |
Top Analysts Covering PG
PG vs Sector & Market
| Metric | PG | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.32 | 2.55 | 2.41 |
| Analyst Count | 19 | 12 | 18 |
| Target Upside | +9.9% | +1188.8% | +14.9% |
| P/E Ratio | 21.54 | -7.38 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $86.28B | $86.58B | $87.60B | 17 |
| 2026-09-30 | $22.70B | $22.90B | $23.35B | 5 |
| 2026-12-31 | $22.62B | $22.82B | $23.28B | 5 |
| 2027-03-31 | $20.86B | $21.05B | $21.47B | 5 |
| 2027-06-30 | $21.85B | $22.05B | $22.49B | 5 |
| 2027-09-30 | $23.39B | $23.60B | $24.07B | 5 |
| 2027-12-31 | $23.28B | $23.49B | $23.96B | 5 |
| 2028-03-31 | $21.48B | $21.67B | $22.10B | 4 |
| 2028-06-30 | $22.42B | $22.62B | $23.08B | 4 |
| 2029-06-30 | $95.50B | $96.12B | $97.26B | 10 |
| 2030-06-30 | $99.05B | $99.70B | $100.88B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $6.87 | $6.93 | $6.99 | 12 |
| 2026-09-30 | $2.00 | $2.02 | $2.08 | 9 |
| 2026-12-31 | $1.91 | $1.93 | $1.98 | 10 |
| 2027-03-31 | $1.60 | $1.62 | $1.66 | 5 |
| 2027-06-30 | $1.56 | $1.58 | $1.62 | 5 |
| 2027-09-30 | $2.09 | $2.12 | $2.17 | 5 |
| 2027-12-31 | $2.01 | $2.04 | $2.09 | 5 |
| 2028-03-31 | $1.68 | $1.70 | $1.74 | 7 |
| 2028-06-30 | $1.66 | $1.68 | $1.72 | 6 |
| 2029-06-30 | $7.99 | $8.06 | $8.19 | 1 |
| 2030-06-30 | $8.43 | $8.50 | $8.63 | 1 |
Frequently Asked Questions
What is the analyst consensus for PG?
The consensus among 19 analysts covering The Procter & Gamble Company (PG) is Buy with an average price target of $167.67.
What is the highest price target for PG?
The highest price target for PG is $192.00, set by Kevin Grundy at BNP Paribas on 2024-09-16.
What is the lowest price target for PG?
The lowest price target for PG is $40.00, set by Alexia Howard at Bernstein on 2023-11-24.
How many analysts cover PG?
19 analysts have issued ratings for The Procter & Gamble Company in the past 12 months.
Is PG a buy or sell right now?
Based on 19 analyst ratings, PG has a consensus rating of Buy (2.32/5) with a +9.9% upside to the consensus target of $167.67.
What are the earnings estimates for PG?
Analysts estimate PG will report EPS of $6.93 for the period ending 2026-06-30, with revenue estimated at $86.58B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.